Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels

Journal of Clinical Gastroenterology

Volumn 44, Issue 6, 2010, Pages 440-447

  Tsutsui, Masaru ^a   Tanaka, Naoki ^a,b   Kawakubo, Masatomo ^c   Sheena, Yo ^d   Horiuchi, Akira ^e   Komatsu, Michiharu ^b   Nagaya, Tadanobu ^b   Joshita, Satoru ^b   Umemura, Takeji ^b   Ichijo, Tetsuya ^b   Matsumoto, Akihiro ^b   Yoshizawa, Kaname ^b   Aoyama, Toshifumi ^a   Tanaka, Eiji ^b   Sano, Kenji ^c  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d SHINSHU UNIVERSITY   (Japan)

^e Showa Inan General Hospital   (Japan)

Author keywords

ALT; AST; cytokeratin 18; NAFLD activity score

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; SYNAPTOPHYSIN; UBIQUITIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MALLORY BODY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; BIOPSY; BLOOD; ENZYMOLOGY; EVALUATION STUDY; JAPAN; LIVER; LIVER DISEASES; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BIOPSY; FATTY LIVER; FEMALE; HUMANS; JAPAN; KERATIN-18; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 77953732583     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181bdefe2     Document Type: Article

References (38)

1. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11:1-16.
2. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature. J Gastroenterol. 2006;41:725-732.
3. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
4. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154-160.
5. Nagaya T, Tanaka N, Komatsu M, et al. Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case. Clin J Gastroenterol. 2008;1:116-121.
6. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
7. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906.
8. Sanai FM, Benmousa A, Al-Hussaini H, et al. Is serum alanine aminotransferase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int. 2008;28:1011-1018.
9. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286-1292.
10. Janig E, Stumptner C, Fuchsbichler A, et al. Interaction of stress proteins with misfolded keratins. Eur J Cell Biol. 2005; 84:329-339.
11. Zatloukal K, French SW, Stumptner C, et al. From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res. 2007;313:2033-2049.
12. Nan L, Dedes J, French BA, et al. Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol. 2006;80:228-240.
13. Kawahara H, Matsuda Y, Takase S. Is apoptosis involved in alcoholic hepatitis? Alcohol Alcohol. 1994;29:113-118.
14. Tanaka N, Tanaka E, Sheena Y, et al. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26:956-963.
15. The Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for the Study of Obesity. New criteria for "obesity disease" in Japan. Circ J. 2002;66:987-992.
16. Komatsu M, Yazaki M, Tanaka N, et al. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J Hepatol. 2008;49:810-820.
17. Tanaka N, Nagaya T, Komatsu M, et al. Insulin resistance and hepatitis C virus: a case-control study of non-obese, nonalcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase. Liver Int. 2008;28:1104-1111.
18. Njemini R, Demanet C, Mets T. Comparison of two ELISAs for the determination of Hsp70 in serum. J Immunol Methods. 2005;306:176-182.
19. Tanaka N, Ichijo T, Okiyama W, et al. Laparoscopic findings in patients with nonalcoholic steatohepatitis. Liver Int. 2006; 26:32-38.
20. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413-418.
21. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33.
22. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol. 2007;13:837-844.
23. Tarantino G, Conca P, Coppola A, et al. Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. Eur J Clin Invest. 2007; 37:48-53.
24. Malik R, Chang M, Bhaskar K, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis clinical research network liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24:564-568.
25. Diab DL, Yerian L, Schauer P, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6:1249-1254.
26. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437-443.
27. Kramer G, Erdal H, Mertens H, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64:1751-1756.
28. Gonsebatt ME, Del Razo LM, Cerbon MA, et al. Arsenite induced oxidative damage in mouse liver is associated with increased cytokeratin 18 expression. Arch Toxicol. 2007; 81:619-626.
29. Begriche K, Igoudjil A, Pessayre D, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28.
30. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
31. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor a (PPARa). J Biol Chem. 1998;273:5678-5684.
32. Tanaka N, Moriya K, Kiyosawa K, et al. PPARa activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118: 683-694.
33. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40: 185-194.
34. Seidel N, Volkmann X, Länger F, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113-120.
35. Shimada M, Hashimoto E, Kaneda H, et al. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res. 2002;24:429-438.
36. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362.
37. Liu R, Pan X, Whitington PF. Increased hepatic expression is a major determinant of serum alanine aminotransferase elevation in mice with nonalcoholic steatohepatitis. Liver Int. 2009;29:337-343.
38. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135:100-110.